Personalized approach to early diagnosis of acute schizophrenia: an observational comparative study

Abstract

BACKGROUND: An acute schizophrenic episode often meets the diagnostic criteria for the ICD-10 category acute and transient psychotic disorders (ATPD, F23), which includes clinically similar conditions of diverse etiologies. The presence of schizophrenic negative symptoms in ATPD signifies their nosological affiliation and determines the therapeutic tactics. Early recognition of the schizophrenic etiology in the first episode of psychosis may contribute to the development of a personalized approach for the management of patients with acute psychotic disorders.

AIM: To evaluate the relationship between the developmental characteristics of psychosis and identify the negative symptoms after its reduction in patients with ATPD with the symptoms of schizophrenia.

MATERIALS AND METHODS: This observational single-center selective comparative study was conducted during 2018–2020. The clinical-psychopathological method was applied to examine patients hospitalized in a psychiatric hospital with ATPD presenting with the symptoms of schizophrenia (F23.1). In order to objectify the results of the study, the positive and negative syndrome scale was used.

RESULTS: The study involved 60 patients (50 men, 10 women) aged 18–46 years (mean age: 21.4±6.0 years). Depending on the presence of negative symptoms after the psychosis reduction at 4 weeks of therapy, the study sample was divided into two groups: 1) the group with negative symptoms (NS+; n=41); 2) the group without any negative symptoms (NS–; n=19). Individuals presenting with negative symptoms were distinguished from those without it based on the more frequent presence of prodromal disorders, subpsychotic, and, particularly, mild negative disorders at the prodromal stage, prolonged development, and long-drawn course of psychosis. The likelihood of negative symptoms detection after the reduction of psychosis was associated with a family history of schizophrenia and other psychiatric disorders, low premorbid social adjustment, prodromal symptoms, and impaired functioning, as well as with a longer duration of psychotic symptoms and its slow development.

CONCLUSION: The likelihood of negative symptoms after the reduction of ATPD with symptoms of schizophrenia was associated with hereditary and premorbid characteristics of patients, prodromal psychopathological and functional abnormalities, as well as the clinical and dynamic characteristics of psychosis. The data obtained from this study may contribute to the early recognition of schizophrenia-spectrum disorders and to the development of a personalized approach for the management of patients with ATPD.

Keywords

disorders / psychotic / schizophrenia / personalized medicine

References

[1] Schürhoff F, Fond G, Berna F, et al. A National network of schizophrenia expert centres: an innovative tool to bridge the research-practice gap. Eur Psychiatry. 2015;30(6):728–735. doi: 10.1016/j.eurpsy.2015.05.004

[2] Schürhoff F., Fond G., Berna F., et al. A National network of schizophrenia expert centres: an innovative tool to bridge the research-practice gap // Eur Psychiatry. 2015. Vol. 30, N 6. Р. 728–735. doi: 10.1016/j.eurpsy.2015.05.004

[3] World Health Organization [Internet]. ICD-10: The International Statistical Classification of Diseases and Related Health Problems (10th rev). Geneva: World Health Organization, 1994 [cited 2022 Jul 14]. Available from: https://apps.who.int/iris/handle/10665/246208?locale-attribute=en&

[4] World Health Organization [Internet]. ICD-10: The International Statistical Classification of Diseases and Related Health Problems (10th rev). Geneva: World Health Organization; 1994 [дата обращения: 14.07.2002]. Доступ по ссылке: https://apps.who.int/iris/handle/10665/246208?locale-attribute=en&

[5] Castagnini AC, Berrios GE. Conceptual Issues in Acute and Transient Psychotic Disorders. Psychopathology. 2022;55(1):10–15. doi: 10.1159/000520087

[6] Castagnini A.C., Berrios G.E. Conceptual Issues in Acute and Transient Psychotic Disorders // Psychopathology. 2022. Vol. 55, N 1. Р. 10–15. doi: 10.1159/000520087

[7] Stern S, Linker S, Vadodaria KC, et al. Prediction of response to drug therapy in psychiatric disorders. Open Biol. 2018;8(5):180031. doi: 10.1098/rsob.180031

[8] Stern S., Linker S., Vadodaria K.C., et al. Prediction of response to drug therapy in psychiatric disorders // Open Biol. 2018. Vol. 8, N 5. P. 180031. doi: 10.1098/rsob.180031

[9] Maj M, van Os J, De Hert M, et al. The clinical characterization of the patient with primary psychosis aimed at personalization of management. World Psychiatry. 2021;20(1):4–33. doi: 10.1002/wps.20809

[10] Maj M., van Os J., De Hert M., et al. The clinical characterization of the patient with primary psychosis aimed at personalization of management // World Psychiatry. 2021. Vol. 20, N 1. Р. 4–33. doi: 10.1002/wps.20809

[11] Shamabadi A, Hasanzadeh A, Akhondzadeh S. Integrating Psychiatry and Medical Biotechnology as a Way to Achieve Scientific, Precision, and Personalized Psychiatry. Avicenna J Med Biotechnol. 2021;13(4):172–175. doi: 10.18502/ajmb.v13i4.7201

[12] Shamabadi A., Hasanzadeh A., Akhondzadeh S. Integrating Psychiatry and Medical Biotechnology as a Way to Achieve Scientific, Precision, and Personalized Psychiatry // Avicenna J Med Biotechnol. 2021. Vol. 13, N 4. P. 172–175. doi: 10.18502/ajmb.v13i4.7201

[13] Lisoway AJ, Chen CC, Zai CC, et al. Toward personalized medicine in schizophrenia: Genetics and epigenetics of antipsychotic treatment. Schizophr Res. 2021;232:112–124. doi: 10.1016/j.schres.2021.05.010

[14] Lisoway A.J., Chen C.C., Zai C.C., et al. Toward personalized medicine in schizophrenia: Genetics and epigenetics of antipsychotic treatment // Schizophr Res. 2021. Vol. 232. Р. 112–124. doi: 10.1016/j.schres.2021.05.010

[15] Collo G, Mucci A, Giordano GM, et al. Negative symptoms of schizophrenia and dopaminergic transmission: translational models and perspectives opened by iPSC techniques. Front Neurosci. 2020;14:632. doi: 10.3389/fnins.2020.00632

[16] Collo G., Mucci A., Giordano G.M., et al. Negative symptoms of schizophrenia and dopaminergic transmission: translational models and perspectives opened by iPSC techniques // Front Neurosci. 2020. Vol. 14. P. 632. doi: 10.3389/fnins.2020.00632

[17] Queirazza FF, Semple DM, Lawrie SM. Transition to schizophrenia in acute and transient psychotic disorders. Br J Psychiatry. 2014;204:299–305. doi: 10.1192/bjp.bp.113.127340

[18] Queirazza F.F., Semple D.M., Lawrie S.M. Transition to schizophrenia in acute and transient psychotic disorders // Br J Psychiatry. 2014. Vol. 204. P. 299–305. doi: 10.1192/bjp.bp.113.127340

[19] Suda К, Hayashi N, Hiraga М. Predicting features of later development of schizophrenia among patients with acute and transient psychotic disorder. Psychiatry Clin Neurosci. 2005;59(2):146–150. doi: 10.1111/j.1440-1819.2005.01349.x

[20] Suda К., Hayashi N., Hiraga М. Predicting features of later development of schizophrenia among patients with acute and transient psychotic disorder // Psychiatry Clin Neurosci. 2005. Vol. 59, N 2. Р. 146–150. doi: 10.1111/j.1440-1819.2005.01349.x

[21] Sajith SG, Chandrasekaran R, Sadanandan Unni KE, Sahai A. Acute polymorphic psychotic disorder: diagnostic stability over 3 years. Acta Psychiatr Scand. 2002;105(2):104–109. doi: 10.1034/j.1600-0447.2002.01080.x

[22] Sajith S.G., Chandrasekaran R., Sadanandan Unni K.E., Sahai A. Acute polymorphic psychotic disorder: diagnostic stability over 3 years // Acta Psychiatr Scand. 2002. Vol. 105, N 2. Р. 104–109. doi: 10.1034/j.1600-0447.2002.01080.x

[23] Castagnini AC, Laursen ТМ, Mortensen РВ, Bertelsen А. Family psychiatric morbidity of acute and transient psychotic disorders and their relationship to schizophrenia and bipolar disorder. Psychol Med. 2013;43(11):2369–2375. doi: 10.1017/S0033291713000044

[24] Castagnini A.C., Laursen Т.М., Mortensen Р.В., Bertelsen А. Family psychiatric morbidity of acute and transient psychotic disorders and their relationship to schizophrenia and bipolar disorder // Psychol Med. 2013. Vol. 43, N 11. Р. 2369–2375. doi: 10.1017/S0033291713000044

[25] Aleshkina GA, Bardenshtein LM. Ostrye i prekhodyashchie psikhoticheskie rasstroistva: monografiya. Moscow: «MEDPRAKTIKA-M»; 2017. (In Russ).

[26] Алешкина Г.А., Барденштейн Л.М. Острые и преходящие психотические расстройства: монография. Москва: «МЕДПРАКТИКА-М», 2017.

[27] Mezquida G, Cabrera B, Bioque M, et al. The course of negative symptoms in first-episode schizophrenia and its predictors: a prospective two-year follow-up. Schizophr Res. 2017;189:84–90. doi: 10.1016/j.schres.2017.01.047

[28] Mezquida G., Cabrera B., Bioque M., et al. The course of negative symptoms in first-episode schizophrenia and its predictors: a prospective two-year follow-up // Schizophr Res. 2017. Vol. 189. Р. 84–90. doi: 10.1016/j.schres.2017.01.047

[29] Ventura J, Subotnik KL, Gitlin MJ, et al. Negative symptoms and functioning during the first year after a recent onset of schizophrenia and 8 years later. Schizophr Res. 2015;161(2–3):407–413. doi: 10.1016/j.schres.2014.10.043

[30] Ventura J., Subotnik K.L., Gitlin M.J., et al. Negative symptoms and functioning during the first year after a recent onset of schizophrenia and 8 years later // Schizophr Res. 2015. Vol. 161, N 2–3. Р. 407–413. doi: 10.1016/j.schres.2014.10.043

[31] Hovington CL, Bodnar M, Joober R, et al. Identifying persistent negative symptoms in first episode psychosis. BMC Psychiatry. 2012;12:224. doi: 10.1186/1471-244X-12-224

[32] Hovington C.L., Bodnar M., Joober R., et al. Identifying persistent negative symptoms in first episode psychosis // BMC Psychiatry. 2012. Vol. 12. Р. 224. doi: 10.1186/1471-244X-12-224

[33] Galderisi S, Mucci A, Bitter I, et al. Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial. Eur Neuropsychopharmacol. 2013;23(3):196–204. doi: 10.1016/j.euroneuro.2012.04.019

[34] Galderisi S., Mucci A., Bitter I., et al. Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial // Eur Neuropsychopharmacol. 2013. Vol. 23, N 3. Р. 196–204. doi: 10.1016/j.euroneuro.2012.04.019

[35] Bardenshtein L, Aleshkina G, Shcherbakova I, Beglyankin N. Acute and transient psychotic disorders: comparison. Eur Psychiatry. 2013;28(Suppl.1):1. doi: 10.1016/S0924-9338(13)75881-4

[36] Bardenshtein L., Aleshkina G., Shcherbakova I., Beglyankin N. Acute and transient psychotic disorders: comparison // Eur Psychiatry. 2013. Vol. 28, Suppl. 1. P. 1. doi: 10.1016/S0924-9338(13)75881-4

[37] Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276. doi: 10.1093/schbul/13.2.261

[38] Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia // Schizophr Bull. 1987. Vol. 13, N 2. Р. 261–276. doi: 10.1093/schbul/13.2.261

[39] MacBeth A, Gumley A. Premorbid adjustment, symptom development and quality of life in first episode psychosis: a systematic review and critical reappraisal. Acta Psychiatr Scand. 2008;117(2):85–99. doi: 10.1111/j.1600-0447.2007.01134.x

[40] MacBeth A., Gumley A. Premorbid adjustment, symptom development and quality of life in first episode psychosis: a systematic review and critical reappraisal // Acta Psychiatr Scand. 2008. Vol. 117, N 2. Р. 85–99. doi: 10.1111/j.1600-0447.2007.01134.x

[41] Compton MT, Gordon TL, Goulding SM, et al. Patient-level predictors and clinical correlates of duration of untreated psychosis among hospitalized first-episode patients. J Clin Psychiatry. 2011;72(2):225–232. doi: 10.4088/JCP.09m05704yel

[42] Compton M.T., Gordon T.L., Goulding S.M., et al. Patient-level predictors and clinical correlates of duration of untreated psychosis among hospitalized first-episode patients // J Clin Psychiatry. 2011. Vol. 72, N 2. Р. 225–232. doi: 10.4088/JCP.09m05704yel

[43] Amoretti S, Verdolini N, Mezquida G, et al. Identifying clinical clusters with distinct trajectories in first-episode psychosis through an unsupervised machine learning technique. Eur Neuropsychopharmacol. 2021;47:112–129. doi: 10.1016/j.euroneuro.2021.01.095

[44] Amoretti S., Verdolini N., Mezquida G., et al. Identifying clinical clusters with distinct trajectories in first-episode psychosis through an unsupervised machine learning technique // Eur Neuropsychopharmacol. 2021. Vol. 47. Р. 112–129. doi: 10.1016/j.euroneuro.2021.01.095

[45] Chang WC, Hui CL, Tang JY, et al. Persistent negative symptoms in first-episode schizophrenia: a prospective three-year follow-up study. Schizophr Res. 2011;133(1–3):22–28. doi: 10.1016/j.schres.2011.09.006

[46] Chang W.C., Hui C.L., Tang J.Y., et al. Persistent negative symptoms in first-episode schizophrenia: a prospective three-year follow-up study // Schizophr Res. 2011. Vol. 133, N 1–3. Р. 22–28. doi: 10.1016/j.schres.2011.09.006

[47] Chan SKW, Chan HYV, Pang HH, et al. Ten-year trajectory and outcomes of negative symptoms of patients with first-episode schizophrenia spectrum disorders. Schizophr Res. 2020;220:85–91. doi: 10.1016/j.schres.2020.03.061

[48] Chan S.K.W., Chan H.Y.V., Pang H.H., et al. Ten-year trajectory and outcomes of negative symptoms of patients with first-episode schizophrenia spectrum disorders // Schizophr Res. 2020. Vol. 220. Р. 85–91. doi: 10.1016/j.schres.2020.03.061

[49] Abramov VA, Lykholetova OI, Putyatin GG. Clinical analysis of initial prodrome of schizophrenia in temporal, gender and age aspects. Journal of Psychiatry and Medical Psychology. 2012;2(29):15–29. (In Russ).

[50] Абрамов В.А., Лихолетова О.И., Путятин Г.Г. Клинический анализ инициального продрома шизофрении во временном и гендерно-возрастном аспектах // Журнал психиатрии и медицинской психологии. 2012. Т. 2, № 29. С. 15–29.

RIGHTS & PERMISSIONS

Eco-Vector